August M. Watanabe, MD, is Chairman of the Board of Kalypsys. Dr. Watanabe retired as Executive Vice President, Science and Technology, Director of Eli Lilly and Company, and President of Lilly Research Laboratories in June 2003. Prior to joining Lilly in 1990, Dr. Watanabe had been a full-time faculty member of the Department of Medicine of Indiana University School of Medicine from 1972 to 1990.
During his tenure at Lilly, the company was recognized for having the strongest pipeline of potential new drug products in the pharmaceutical industry. During the last three years, Lilly has more than doubled the number of new drugs it has on the market. While with Lilly, he served for six years as Chairman of the Science and Technology Section of the Pharmaceutical Research and Manufacturing Association of America (PhRMA).
He is Chairman of the Board of BioCrossroads, a partner in Twilight Venture Partners (TVP), and a director of Guidant Corporation, QuatRx Corporation, Endocyte Corporation, Reliant Corporation, Ambrx Corporation, the Damon Runyon Cancer Research Foundation, the Indiana University Foundation, the Regenstrief Foundation, the Indiana State Symphony Society and Christel House International.